Gender differences regarding interest in opioid agonist treatment with hydromorphone: a cross-sectional study of syringe service program participants

Abstract Background In the United States, only 15–20% of people with opioid use disorder (OUD) receive medications for OUD annually. Injectable opioid agonist treatment with hydromorphone (iOAT-H) is a novel approach that reduces non-prescribed opioid use. However, interest in iOAT-H among women, wh...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Vitaliy Lasiychuk, Megan Ghiroli, Teresa López-Castro, Aaron D. Fox
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	BMC 2025-08-01
Rangatū:	Harm Reduction Journal
Ngā marau:	Opioid use disorder Injectable opioid agonist treatment Hydromorphone Gender Medications for opioid use disorder (MOUD)
Urunga tuihono:	https://doi.org/10.1186/s12954-025-01300-1
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!